HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

Abstract
Excessive iron absorption is one of the main features of β-thalassemia and can lead to severe morbidity and mortality. Serial analyses of β-thalassemic mice indicate that while hemoglobin levels decrease over time, the concentration of iron in the liver, spleen, and kidneys markedly increases. Iron overload is associated with low levels of hepcidin, a peptide that regulates iron metabolism by triggering degradation of ferroportin, an iron-transport protein localized on absorptive enterocytes as well as hepatocytes and macrophages. Patients with β-thalassemia also have low hepcidin levels. These observations led us to hypothesize that more iron is absorbed in β-thalassemia than is required for erythropoiesis and that increasing the concentration of hepcidin in the body of such patients might be therapeutic, limiting iron overload. Here we demonstrate that a moderate increase in expression of hepcidin in β-thalassemic mice limits iron overload, decreases formation of insoluble membrane-bound globins and reactive oxygen species, and improves anemia. Mice with increased hepcidin expression also demonstrated an increase in the lifespan of their red cells, reversal of ineffective erythropoiesis and splenomegaly, and an increase in total hemoglobin levels. These data led us to suggest that therapeutics that could increase hepcidin levels or act as hepcidin agonists might help treat the abnormal iron absorption in individuals with β-thalassemia and related disorders.
AuthorsSara Gardenghi, Pedro Ramos, Maria Franca Marongiu, Luca Melchiori, Laura Breda, Ella Guy, Kristen Muirhead, Niva Rao, Cindy N Roy, Nancy C Andrews, Elizabeta Nemeth, Antonia Follenzi, Xiuli An, Narla Mohandas, Yelena Ginzburg, Eliezer A Rachmilewitz, Patricia J Giardina, Robert W Grady, Stefano Rivella
JournalThe Journal of clinical investigation (J Clin Invest) Vol. 120 Issue 12 Pg. 4466-77 (Dec 2010) ISSN: 1558-8238 [Electronic] United States
PMID21099112 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antimicrobial Cationic Peptides
  • DNA Primers
  • HAMP protein, human
  • Hamp protein, mouse
  • Hepcidins
  • Iron, Dietary
  • Recombinant Proteins
  • Iron
Topics
  • Animals
  • Antimicrobial Cationic Peptides (genetics, therapeutic use)
  • Base Sequence
  • DNA Primers (genetics)
  • Disease Models, Animal
  • Erythropoiesis (drug effects)
  • Gene Expression
  • Hepcidins
  • Humans
  • Iron (metabolism)
  • Iron Overload (blood, drug therapy, metabolism)
  • Iron, Dietary (administration & dosage)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Mutant Strains
  • Mice, Transgenic
  • Recombinant Proteins (genetics, therapeutic use)
  • beta-Thalassemia (blood, drug therapy, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: